US Patent 8,685,443: Claim Scope, Expiration, Orange Book Position, and Opioid Patent Landscape

US Patent No. 8,685,443 protects a multipart opioid dosage form designed to deter abuse by combining a releasable opioid agonist with sequestered naltrexone. The patent’s central limitation is structural and functional: naltrexone must be contained in a sequestering subunit, protected by a surfactant-containing blocking agent, while the opioid agonist is applied over the subunit in releasable form.

The claims are method-of-treatment claims, not stand-alone composition claims. The strongest commercial embodiment identified in claim 10 is a capsule containing composite subunits with morphine, naltrexone, Eudragit RSPO and sodium lauryl sulfate.

What does US Patent 8,685,443 cover?

The patent covers administering abuse-deterrent opioid dosage forms containing multiple composite subunits. Each subunit must contain the following elements:

Required element	Claim requirement
Dosage form	A plurality of composite subunits
Sequestering subunit	Contains naltrexone
Blocking agent	Contains a surfactant
Functional effect	Substantially prevents release of naltrexone in the gastrointestinal tract
Opioid layer	Opioid agonist is overcoated onto the sequestering subunit
Opioid release	Opioid agonist is in releasable form
Administration	Administered to a human to treat pain

The invention is directed to an abuse-deterrent configuration. Under normal oral use, the opioid is intended to provide analgesia while the naltrexone remains sequestered. If the dosage form is manipulated in a manner that defeats the subunit structure, the naltrexone is intended to counteract opioid effects.

The claim does not require a particular abuse route, crushing method, extraction method or overdose event. It requires the claimed dosage form and administration for treating pain.

How broad is independent claim 1?

Claim 1 has moderate breadth but contains several narrowing limitations.

1. “A plurality of composite subunits”

The claim requires more than one composite subunit. A single monolithic tablet or single coated particle would face a substantial non-infringement argument unless the product could properly be characterized as containing multiple claimed subunits.

The term “composite subunit” is functional and structural. It is not merely a mixture of naltrexone and opioid. The subunit must include the naltrexone-containing sequestering component, the blocking agent and the opioid overcoat.

2. Naltrexone must be sequestered

Naltrexone must be present in a sequestering subunit. A formulation that contains naltrexone as a freely dissolving ingredient, or that places naltrexone in a separate immediate-release layer, would not necessarily satisfy this limitation.

The claim focuses on preventing naltrexone release in the gastrointestinal tract. It does not expressly require complete prevention. The phrase “substantially prevents” creates a performance limitation that would likely be assessed through dissolution testing, extraction studies and formulation characterization.

3. The blocking agent must contain a surfactant

A surfactant is mandatory in claim 1. The dependent claims identify sodium lauryl sulfate, also called sodium dodecyl sulfate, as one specific surfactant.

This limitation distinguishes the claimed technology from abuse-deterrent formulations that rely only on waxes, hydrophobic polymers, ion-exchange resins or physical barriers without a surfactant-containing blocking system.

4. The opioid must be an overcoat

The opioid agonist must be applied over the sequestering subunit in releasable form. A formulation in which the opioid and naltrexone are blended throughout the same matrix may not meet the overcoating limitation.

The overcoat requirement creates a potentially important design-around avenue. A competitor could evaluate a multilayer tablet, matrix system, osmotic system or separate-pellet system in which the opioid is not technically an overcoat on the naltrexone-containing subunit.

5. The claim is limited to pain treatment in humans

Claim 1 requires administration to a human being for treatment of pain. It is not a general formulation claim. Manufacturing, formulation and possession claims are not expressly recited in the independent claim.

That distinction affects enforcement. A patent owner would generally need to show that a party directly administers, sells for the claimed treatment, induces use of the claimed method, or contributes to an infringing treatment method. A generic manufacturer may face a narrower risk if its proposed labeling omits the patented method or if the dosage form does not satisfy every structural limitation.

Which opioid agonists are covered?

Claim 2 limits the opioid agonist to morphine, hydromorphone, oxycodone or hydrocodone.

Claim	Opioid scope
Claim 1	Opioid agonist generally
Claim 2	Morphine, hydromorphone, oxycodone or hydrocodone
Claim 3	Morphine
Claim 10	Morphine, in a capsule with the specified excipients and subunit architecture

Claim 1 potentially reaches opioid agonists outside the four named compounds, subject to claim construction and written-description support. Claims 2, 3 and 10 provide narrower fallback positions.

The patent therefore has its greatest commercial relevance to abuse-deterrent oral formulations of morphine and, depending on product design, other conventional opioid agonists.

What formulations are protected by claims 4 through 10?

The dependent claims progressively define a particular coating and capsule implementation.

Claim	Additional limitation
4	Blocking agent also contains a pharmaceutically acceptable hydrophobic material
5	Hydrophobic material is insoluble in the gastrointestinal tract
6	Hydrophobic material is a copolymer of acrylic acid and methacrylic acid
7	Hydrophobic material is Eudragit RSPO
8	Surfactant is sodium lauryl sulfate
9	Composite subunits are contained in a capsule
10	Capsule; Eudragit RSPO; sodium lauryl sulfate; morphine

Claim 10 is the most commercially specific claim. It requires the combination of:

A capsule;
Multiple composite subunits;
Naltrexone-containing sequestering subunits;
A blocking agent containing Eudragit RSPO;
Sodium lauryl sulfate;
Morphine as the opioid agonist;
Morphine overcoated in releasable form; and
Administration to a human to treat pain.

Eudragit RSPO

Eudragit RSPO is a water-insoluble, permeability-controlling acrylic polymer used in modified-release coatings. Its presence in claim 10 narrows the claim materially. A formulation using a different hydrophobic polymer may avoid claim 10 while remaining exposed to claim 1 or claim 4, depending on the formulation’s other characteristics.

Sodium lauryl sulfate

Sodium lauryl sulfate narrows the surfactant limitation to a defined excipient. A substitute surfactant could avoid claim 8 and claim 10, but would not necessarily avoid claim 1, which covers a blocking agent comprising a surfactant generally.

Is claim 6 properly dependent on claim 1?

As reproduced in the question, claim 6 refers to “the pharmaceutically acceptable hydrophobic material,” although claim 1 does not expressly require that material. Claim 4 introduces the hydrophobic-material limitation.

This creates a dependency and antecedent-basis issue in the supplied claim text. The official patent grant should control for litigation analysis. If the issued claim actually depends from claim 4 rather than claim 1, the defect disappears. If the issued text is exactly as reproduced, claim construction would determine whether the reference incorporates the limitation from claim 4 by necessary implication or whether the claim is indefinite or otherwise vulnerable.

This issue does not affect claim 10, which expressly identifies the hydrophobic material, surfactant, opioid and capsule.

When does US Patent 8,685,443 lose exclusivity?

The patent was granted on April 1, 2014. Its term is based on the earliest effective nonprovisional filing or priority date, subject to patent-term adjustment and any applicable extension.

Public patent records associate the patent family with a September 2009 priority period and a nominal term extending into 2029. The expected nominal expiration is approximately September 2029, subject to the USPTO-calculated patent-term adjustment. A definitive freedom-to-operate date should use the USPTO Patent Examination Data System term calculation rather than a simple 20-year estimate. (U.S. Patent No. 8,685,443, 2014; United States Patent and Trademark Office, n.d.)

The patent does not appear to be a biologic patent and is not subject to biosimilar exclusivity rules. Its relevant competitors are generic opioid manufacturers and sponsors developing abuse-deterrent opioid formulations.

Exclusivity timeline

Event	Approximate date or status
Priority period	2009
US patent grant	April 1, 2014
Nominal patent expiry	Approximately 2029
FDA regulatory exclusivity	Product-specific; separate from patent term
Biosimilar exclusivity	Not applicable
Generic entry	Governed by patent, Orange Book and regulatory barriers

FDA exclusivity and patent protection are separate. Any New Chemical Entity, orphan-drug or other FDA exclusivity period would not extend automatically because the product uses an abuse-deterrent formulation. (FDA, 2023a; FDA, 2023b.)

What is the Orange Book status of US Patent 8,685,443?

The patent’s commercial relevance is linked to abuse-deterrent extended-release morphine products, particularly morphine sulfate and naltrexone formulations such as Embeda.

The Orange Book determines whether a listed patent can trigger a Hatch-Waxman patent certification and, in qualifying circumstances, a 30-month stay after a Paragraph IV notice. Listing status must be evaluated against the specific NDA, strength, dosage form and patent listing record. A patent can be legally relevant to a product without being listed for every strength or dosage form. (FDA, n.d.-a.)

For an ANDA applicant, the relevant questions are:

Is US 8,685,443 listed against the reference listed drug?
Does the ANDA product have the same dosage form and route?
Does the proposed label include the patented method of use?
Does the formulation satisfy the structural limitations?
Has the applicant filed a Paragraph IV certification?
Has the NDA holder brought suit within 45 days?

A Paragraph IV certification is not itself an admission of infringement. It is a statutory position that the listed patent is invalid, unenforceable or will not be infringed by the proposed ANDA product. (21 U.S.C. § 355(j)(2)(A)(vii)(IV).)

What generic entry risks exist?

A generic applicant faces different risks depending on whether it copies the patented subunit architecture or develops a materially different product.

High-risk design

A product is exposed to the core patent if it has:

Multiple pellets or beads;
Naltrexone in a sequestering subunit;
A surfactant-containing barrier;
An opioid layer over the naltrexone subunit;
Morphine or another listed opioid;
A capsule dosage form;
Labeling for pain treatment.

A morphine capsule using Eudragit RSPO and sodium lauryl sulfate would create the clearest risk under claim 10.

Intermediate-risk design

A product may remain exposed to claim 1 or claim 4 if it changes:

The polymer;
The surfactant;
The capsule shell;
The opioid;
The coating thickness;
The release profile.

Changing one dependent-claim limitation does not avoid an independent claim.

Lower-risk design

Potentially lower-risk architectures include:

A matrix tablet without overcoated subunits;
A dosage form in which naltrexone is not sequestered;
Separate opioid and antagonist populations that are not composite subunits;
A non-surfactant barrier system;
A formulation that does not substantially prevent gastrointestinal naltrexone release;
A product whose labeling does not practice the claimed pain-treatment method.

These are design-around concepts, not legal conclusions. Literal infringement and infringement under the doctrine of equivalents would depend on the final product, manufacturing process and labeling.

How strong is the patent estate?

The patent has meaningful protection at the formulation architecture level, but the independent claim is narrower than a pure composition claim.

Strengths

The patent combines several features in one claim:

Sequestered antagonist;
Surfactant-containing blocking agent;
Gastrointestinal-release prevention;
Opioid overcoat;
Multiple subunits;
Human pain treatment.

Those limitations can make a direct copy easier to identify. Claim 10 provides a detailed fallback claim covering a commercially plausible morphine capsule.

Vulnerabilities

The principal vulnerabilities are:

Functional language. “Substantially prevents release” may require technically demanding proof of the claimed performance.
Overcoat construction. The parties may dispute what constitutes an opioid “overcoated” onto a sequestering subunit.
Subunit definition. A competitor may challenge whether its dosage form contains the required composite subunits.
Prior art. Abuse-deterrent opioid systems using opioid antagonists, polymer coatings and multiparticulates may create novelty or obviousness arguments.
Method-claim limits. The claims do not expressly cover every manufacture, sale or possession scenario.
Dependency issue. The supplied wording for claim 6 raises an antecedent-basis question.

The patent is stronger against a close formulation copy than against a genuinely different abuse-deterrent architecture.

What prior-art and patent-landscape categories matter?

The relevant landscape includes five overlapping technology groups.

Opioid-antagonist sequestration

These patents cover combining an opioid with naltrexone or another antagonist so that the antagonist is inactive during intended use but becomes available after manipulation.

Multiparticulate capsules

These patents focus on pellets, beads or microspheres containing different layers or functional zones. Multiparticulate designs can improve dose distribution but also create claim exposure where the opioid is coated onto antagonist-containing particles.

Hydrophobic and acrylic coatings

Eudragit polymers, ethylcellulose, waxes and related materials are common controlled-release and abuse-deterrence tools. A patent directed to a specific polymer-surfactant combination may have narrower but more enforceable commercial scope than a broad functional coating claim.

Abuse-deterrent morphine

Morphine sulfate/naltrexone products are the closest product category. Embeda is the principal reference product associated with this technology. The FDA has recognized abuse-deterrent formulations through product labeling and abuse-deterrence guidance, but FDA recognition does not establish patent validity or infringement. (FDA, 2015.)

Other abuse-deterrent opioids

Oxycodone, hydrocodone and hydromorphone products use different approaches, including physical barriers, gelling agents, antagonist combinations and aversive agents. Their patents may overlap at a high technical level but avoid US 8,685,443 if they do not use the claimed composite-subunit and overcoat arrangement.

Which companies are relevant to the patent landscape?

The competitive landscape includes:

Company or group	Relevance
Purdue Pharma and related opioid businesses	Abuse-deterrent opioid development and patent activity
Pfizer and King Pharmaceuticals	Commercial association with Embeda
Generic opioid manufacturers	Potential ANDA applicants and Paragraph IV challengers
Abuse-deterrent formulation developers	Competing polymer, matrix and multiparticulate platforms
Contract manufacturers	Potential sources of manufacturing and process-IP risk

The ownership, licensing and enforcement history must be separated from product branding. A company may own a patent, market the reference product, license the technology or hold only a related patent family.

What patent litigation and settlement issues affect entry?

A Paragraph IV dispute would likely focus on four questions:

Whether the ANDA product has composite subunits;
Whether naltrexone is substantially protected from gastrointestinal release;
Whether the opioid is overcoated in releasable form;
Whether the proposed use is treatment of pain in humans.

A settlement could provide a licensed entry date before patent expiration, subject to antitrust scrutiny and FDA approval. Settlement terms may include:

Authorized generic rights;
Delayed generic launch;
Formulation restrictions;
Manufacturing licenses;
No-challenge provisions;
Royalty arrangements;
Supply obligations.

A public litigation search should distinguish cases involving US 8,685,443 from cases involving related Embeda patents. Related-patent litigation may concern the same product but different claim limitations.

How does US 8,685,443 compare with formulation and method-of-use patents?

Patent type	Primary protection	Relevance to US 8,685,443
Composition patent	Ingredients and physical arrangement	Often broader than the method claims here
Formulation patent	Pellets, coatings, polymers and release profile	Closest technical overlap
Method-of-use patent	Treating pain or another indication	Similar statutory format to this patent
Manufacturing patent	Coating, layering or encapsulation process	Separate infringement pathway
Drug-product patent	Specific approved strength and dosage form	May create Orange Book risk
Regulatory exclusivity	FDA approval-based period	Separate from patent rights

US 8,685,443 is best characterized as a formulation-specific method patent. Its commercial value depends on whether a marketed product practices the claimed physical configuration and whether the relevant use is included in the approved or proposed label.

Key Takeaways

US 8,685,443 targets abuse-deterrent opioid formulations using sequestered naltrexone.
Claim 1 requires multiple composite subunits, a surfactant-containing blocking agent, substantial gastrointestinal prevention of naltrexone release and an opioid overcoat.
Morphine, hydromorphone, oxycodone and hydrocodone are expressly identified in dependent claims.
Claim 10 is the narrowest and most product-specific claim, covering a morphine capsule using Eudragit RSPO and sodium lauryl sulfate.
The patent is a method patent, not a broad stand-alone composition claim.
The nominal patent term extends approximately to 2029, subject to USPTO term adjustment.
Generic risk is highest for multiparticulate morphine capsules that reproduce the naltrexone-sequestering and opioid-overcoat architecture.
A matrix tablet, non-sequestered antagonist design or non-overcoated opioid architecture may provide a design-around path.
FDA Orange Book listing, ANDA certification status and Paragraph IV litigation must be evaluated against the specific reference product and dosage form.
The principal legal pressure points are claim construction, functional proof of “substantially prevents,” the meaning of “composite subunit” and the definition of “overcoated.”

FAQs

Does US 8,685,443 claim Embeda specifically?

The claims appear directed to the same general abuse-deterrent technology associated with morphine sulfate and naltrexone multiparticulate capsules. Product-specific coverage depends on the approved formulation and the patent’s Orange Book listing.

Can a generic avoid the patent by replacing Eudragit RSPO?

Replacing Eudragit RSPO may avoid claims 7 and 10, but it would not automatically avoid claim 1 or claim 4. The generic would still need to assess whether its alternative polymer performs the claimed blocking function.

Does using oxycodone instead of morphine avoid the patent?

Not necessarily. Claim 2 expressly includes oxycodone. A product using oxycodone could still infringe if it satisfies the remaining structural and functional limitations.

Is sodium lauryl sulfate required in every claim?

No. Sodium lauryl sulfate appears in claims 8 and 10. Claim 1 requires a surfactant generally, so a different surfactant could remain within claim 1.

Are biosimilar rules relevant to this patent?

No. The patent concerns an orally administered small-molecule opioid formulation. Generic-drug rules under the ANDA pathway, rather than biosimilar rules, are the relevant regulatory framework.

References

Food and Drug Administration. (2015). Abuse-deterrent opioid analgesics: Evaluation and labeling guidance for industry. U.S. Department of Health and Human Services.
Food and Drug Administration. (2023a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
Food and Drug Administration. (2023b). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,685,443: Abuse-resistant dosage forms. U.S. Department of Commerce.
United States Patent and Trademark Office. (n.d.). Patent examination data system and patent term adjustment information. U.S. Department of Commerce.
21 U.S.C. § 355. (2023). New drugs and abbreviated new drug applications.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003270778	⤷ Start Trial
Australia	2009251081	⤷ Start Trial
Canada	2499550	⤷ Start Trial
China	1703200	⤷ Start Trial
Cyprus	1120720	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,685,443